Company Overview
Entrada Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to transforming patient lives by developing a novel class of medicines that engage intracellular targets previously considered inaccessible. The company's strategic focus centers on its proprietary Endosomal Escape Vehicle technology, which forms the basis of its therapeutic candidates designed to reach difficult-to-target biological sites. This enterprise functions within the healthcare sector and specifically within the biotechnology industry, positioning it as a developer of innovative biological therapeutics rather than a manufacturer of generic pharmaceuticals or medical devices. As of the latest available data, the company maintains a market capitalization of $461.33M, generating annual revenue of $25.42M, and employs a workforce of 152 individuals. These financial and operational metrics indicate that Entrada Therapeutics is a small-cap entity with limited revenue generation relative to its valuation, suggesting the market prices the stock primarily on future clinical potential rather than current operational earnings or cash flow stability.
Financial Health
The company reports a trailing twelve-month revenue of $25.42M while recording a net income loss of $-143,750,000 and an EBITDA of $-151,902,000, revealing a significant gap between top-line sales and bottom-line profitability driven by substantial operational expenses. This disparity highlights a cost structure typical of early-stage biotechnology firms where research and development expenditures vastly exceed current revenue streams, resulting in negative earnings despite modest sales figures. Free cash flow stands at $-76,957,752, indicating that the company consumes more cash than it generates from operations, which limits immediate financial flexibility and necessitates reliance on external capital sources to fund ongoing activities. Margins across the board reflect this developmental stage, with a gross margin of 0.0%, an operating margin of -3103.0%, and a profit margin of 0.0%, all signaling that the company has not yet achieved scalable profitability or cost efficiencies. Regarding solvency, the company holds $295.70M in cash against $50.93M in debt, resulting in a debt-to-equity ratio of 16.64, which suggests a highly leveraged balance sheet relative to equity though the absolute debt load is manageable given the cash reserves. The current ratio of 12.53 demonstrates robust short-term liquidity, as the company possesses more than twelve times the current assets required to cover its short-term liabilities without immediate refinancing. Return on equity is recorded at -39.1% and return on assets at -21.6%, metrics that reveal management has yet to generate positive returns on the capital deployed, consistent with the high burn rates inherent in pre-revenue biopharmaceutical development.
Valuation Assessment
Valuation multiples for the company are distorted by the lack of earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -3.44, implying that the market is not valuing the stock based on current or near-term profitability but rather on asset backing or future clinical milestones. The price-to-book ratio is 1.42, indicating that the market values the company at 1.42 times its book value, which may suggest a slight premium over the net asset value or simply reflect the intangible value of its intellectual property and pipeline. Alternative valuation metrics such as the price-to-sales ratio of 18.15 and an EV/EBITDA of -1.24 provide further context, showing that investors are willing to pay a high multiple for every dollar of revenue despite the negative earnings multiple, likely due to expectations of future commercial success. Price metrics show a 52-week high of $13.65 and a 52-week low of $4.93; without a specific current price provided in the source data, the relative positioning cannot be calculated, but the wide range indicates significant price volatility over the past year. The beta is recorded as -0.12, an anomalous value for equities that suggests the stock price moves inversely to the broader market or exhibits negligible correlation, implying unique risk factors distinct from general market movements.
Growth & Income
The company experienced a revenue growth year-over-year of -96.5%, while earnings growth is listed as N/A due to prior losses, indicating a contraction in sales rather than a growth trajectory. Because the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not return capital to shareholders through distributions, instead retaining any potential earnings to reinvest into research and development. The absence of a dividend yield confirms that Entrada Therapeutics follows a growth-oriented capital allocation strategy common in clinical-stage biotechnology, where all available funds are directed toward advancing clinical trials and securing regulatory approvals rather than providing income to investors. Consequently, the overall growth and income profile is characterized by significant revenue contraction and a total absence of dividend income, reflecting a high-risk, high-reward investment vehicle focused entirely on future product development rather than current financial returns.